Merrimack Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merrimack Pharmaceuticals, Inc.
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.
Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut.
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
Plus deals involving Scynexis/Hansoh, Cend/Qilu, Apollomics/Edison, Apollomics/Iterion, Apollomics/Nuance, Aerami/Chance, Antibe/Nuance, Ildong/Arbormed
- Drug Delivery
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Other Names / Subsidiaries
- Hermes Biosciences, Inc.